Posted by Michael Wonder on 30 Oct 2024
US FDA grants Prolong Pharmaceuticals FDA fast track designation for novel stroke therapy (PP-007) in HEMERA-1 clinical study
30 October 2024 - Prolong Pharmaceuticals announced today that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has received fast track designation from the US FDA for the treatment of acute ischaemic stroke.
PP-007 is currently being evaluated for safety and efficacy in an on-going US based clinical trial, HEMERA-1.
